49.70 -0.49 (-0.98%)
TEVA
Stock Details
Last Trade:49.70 Change:-0.49 (-0.98%) Prev Close:50.19 Open: 50.00 Days Range:49.24 – 50.10 52 Week Range: 35.89 - 50.35 Volume:3311520 P/E: N/AEPS:0.00
View AllRecent Alerts 07/02/09
Recent Alert on 06/29/09 at 3:11pm
Teva (TEVA) and Antares (AIS) Announce FDA Approval of Needle-Free Injector for Tev-Tropin(R)
Teva (TEVA) and Antares (AIS) Announce FDA Approval of Needle-Free Injector for Tev-Tropin(R)
Earlier this morning, Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and its partner, Antares Pharma, Inc. (Amex: AIS) today announced the approval of a Supplemental New Drug Application, which added "needle-free injection" to its Tev-Tropin(R)... Read More
Recent Alert on 06/25/09 at 8:10am
Teva Pharmaceutical (TEVA) and Active Biotech Complete Enrollment in Second Oral Laquinimod Phase III MS Clinical Trial
Teva Pharmaceutical (TEVA) and Active Biotech Complete Enrollment in Second Oral Laquinimod Phase III MS Clinical Trial
Recent Alert on 06/25/09 at 8:09am
Teva Pharma (TEVA) and Active Biotech Complete Patient Enrollment for Second Pivotal Phase III Trial of Laquinimod
Teva Pharma (TEVA) and Active Biotech Complete Patient Enrollment for Second Pivotal Phase III Trial of Laquinimod
Recent Alert on 06/24/09 at 7:03am
Goldman Sachs Lifts Estimates and Price Target on Teva Pharma (TEVA)
Goldman Sachs Lifts Estimates and Price Target on Teva Pharma (TEVA)
Recent Alert on 05/14/09 at 4:33pm
Gilead Sciences (GILD) Files Second Suit Against Teva Pharma (TEVA)
Gilead Sciences (GILD) Files Second Suit Against Teva Pharma (TEVA)
View AllRecent Press Releases
Press Release on 06/29/09 at 8:00am
Teva and Antares Announce FDA Approval of Needle-Free Injector Product for Administration of Tev-Tropin(R) (Human Growth Hormone)
Teva and Antares Announce FDA Approval of Needle-Free Injector Product for Administration of Tev-Tropin(R) (Human Growth Hormone)